1 Year Ago
1 Min Read

ISEE up 9% after study results.

Iveric Bio Inc (ISEE) is trading 9% higher at $16.24 today. The Health Care sector is having a generally cheery day, this hasn't really affected the stock's share price, as it outmatching other names in the space.

-Iveric Bio reports positive top-line data from the phase III GATHER2 study
-The study was evaluating the company's investigational candidate, Zimura, for the treatment of geographic atrophy
-The clinical trial met its primary endpoint of mean rate of growth of GA over 12 months with statistical significance and a positive safety profile
-CEO of Iveric Bio said the results from the study provide the basis for an NDA, which they are planning to submit by the end of first quarter of 2023

Iveric Bio Inc has been trading between a 52-week high of $19.35 and a 52-week low of $8.37. The stock has a market cap of $1.92 Billion.

IVERIC bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases.

As you can imagine, the internet had a few things to say about the price move. Here's a few choice comments from the Reddit Traderverse™:

jobmarketsucks - 1 upvotes - source
Got puts on ISEE. Then it decided to go back up to $15. ![img](emote|t5_2th52|4260)

ianm92234 - 0 upvotes - source
ISEE (Iveric) been going up due to successful drug trials, racing one other company to market. In at 13.90 it could go crazy when fda approves patent